OBJECTIVES To evaluate the cost-effectiveness of a new generation integrase inhibitor (INI), dolutegravir  (DTG), in France, in treatment-experienced (TE) and INI-naïve HIV adults with at least two- classes resistance, compared to raltegravir (RAL), by adapting previously published Anti-Retroviral Analysis by Monte Carlo Individual Simulation (ARAMIS) model. METHODS ARAMIS is a microsimulation model using 500,000 simulations with a lifetime analytic time horizon and a monthly cycle length. Markov health states were defined by HIV health state (with or without opportunistic infection). The initial cohort, efficacy and safety data of the model were derived from SAILING, a phase III pivotal study. Antiretroviral treatment (ART) algorithms were based on French guidelines (2013) and experts opinion according to patients’ treatment history, including INI resistance status. Costs were mainly derived from the study by Sloan et al. (2012), which included routine HIV and opportunistic infection care, and death. RESULTS The ARAMIS model indicates that DTG compared to RAL over a life time is associated with additional quality-adjusted life years (QALY; 10.751 versus